SG Americas Securities LLC Buys 53,795 Shares of Illumina, Inc. $ILMN

SG Americas Securities LLC grew its stake in Illumina, Inc. (NASDAQ:ILMN) by 775.9% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,728 shares of the life sciences company’s stock after purchasing an additional 53,795 shares during the quarter. SG Americas Securities LLC’s holdings in Illumina were worth $5,767,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. Next Capital Management LLC purchased a new stake in shares of Illumina in the second quarter valued at about $341,000. CWM LLC boosted its holdings in Illumina by 112.9% during the second quarter. CWM LLC now owns 76,711 shares of the life sciences company’s stock worth $7,319,000 after purchasing an additional 40,676 shares during the last quarter. Generali Asset Management SPA SGR grew its position in Illumina by 51.6% in the 3rd quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company’s stock worth $2,113,000 after purchasing an additional 7,574 shares in the last quarter. Andra AP fonden increased its stake in Illumina by 426.3% in the 2nd quarter. Andra AP fonden now owns 102,491 shares of the life sciences company’s stock valued at $9,779,000 after buying an additional 83,017 shares during the last quarter. Finally, Bourgeon Capital Management LLC lifted its position in shares of Illumina by 76.4% during the 2nd quarter. Bourgeon Capital Management LLC now owns 141,896 shares of the life sciences company’s stock worth $13,538,000 after buying an additional 61,468 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling

In other news, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the transaction, the insider directly owned 17,887 shares of the company’s stock, valued at $2,434,241.83. This trade represents a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Scott Gottlieb acquired 500 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were bought at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the purchase, the director owned 12,523 shares in the company, valued at $1,529,433.99. This trade represents a 4.16% increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 2.60% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on ILMN. Canaccord Genuity Group upped their target price on Illumina from $112.00 to $130.00 and gave the company a “hold” rating in a report on Monday, December 22nd. Cowen restated a “hold” rating on shares of Illumina in a research note on Wednesday. UBS Group raised their target price on Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Weiss Ratings reissued a “hold (c-)” rating on shares of Illumina in a report on Monday, December 29th. Finally, Robert W. Baird set a $109.00 price objective on shares of Illumina in a report on Friday, October 31st. Five analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $122.56.

Illumina Trading Down 3.3%

Shares of ILMN opened at $141.07 on Friday. The business has a 50-day moving average of $130.01 and a 200 day moving average of $109.77. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $153.06. The firm has a market cap of $21.56 billion, a P/E ratio of 31.63, a price-to-earnings-growth ratio of 2.35 and a beta of 1.41. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.16 by $0.18. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The company’s revenue was up .4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.